GoldenGolden
Advanced Search
DCPrime

DCPrime

DCPrime is a biotechnology company developing cancer immunotherapies.

DCPrime is a company that develops clinical stage, novel cancer immunotherapies that are based on their DCOne platform. The company was founded by Ada Kruisbeek in 2006, in Leiden, Zuid-Holland, The Netherlands.

The company's vaccines are designed for the purpose of relapse, and are designed to be administered after a standard care therapy. The relapse vaccine is used for the purpose of reinforcing a patient's immune system while it is healthy.

DCPrime's vaccine, the DCP-001, is a cell-based vaccine that is designed to fight against blood cancers known for relapsing in a patient. The product is in Phase II clinical trials for the purpose of treating acute myeloid leukemia. The company is primarily focused on developing therapeutic candidates for treating hematological malignancies that have a high risk of relapse, which would allow patients to avoid repeat treatments of chemotherapy or bone marrow transplants. The trials are being evaluated in patients with AML, who have responded to chemotherapy treatment, but cannot undergo bone marrow transplant procedures.

The company signed a licensing agreement with Glycotope in order to combine and advance their cancer vaccination and therapeutic antibody platforms in September of 2020.

Timeline

November 5, 2020
DCPrime presents Interim Clinical Data of adVANCE II Trial at ASH 2020 Meeting
September 21, 2020
DCPrime and Glycotope sign a licensing agreement
March 26, 2018
DCPrime raises a $18,600,000 venture round from Van Herk Ventures.
January 26, 2016
DCPrime raises a $6,060,000 grant from Horizon 2020.
July 9, 2015
DCPrime raises a $1,320,000 private equity.
2005
DCPrime was founded by Dr. Ada Kruisbeek.

Funding rounds

People

Name
Role
LinkedIn

Dharminder Chahal

Supervisory Board

Erik Manting

CEO

Jeroen Rovers

CMO

Further reading

Title
Author
Link
Type
Date

DCPrime and Apceth Biopharma Collaborate on Cancer Vaccines

Pharmaceutical Technology Editors

Web

DCPrime and apceth Biopharma GmbH Announce Manufacturing Partnership

Acapeth

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

DCPrime

Erik Manting

Leiden, Zuid-Holland, The Netherlands

Immunotherapeutics

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.